SCIENTIFIC HUB

Follow the evidence.

SCIENTIFIC LITERATURE · PPR

Magnesium sulfate protects retinal dopaminergic neurons in rats with 6-OHDA-induced Parkinson’s disease

· 2023-10-27

DOI: 10.21203/rs.3.rs-3450601/v1

Check source for accessPreprintOriginal source ↗

Research overview

The text below is the source article’s original abstract under a verified reuse license. cc by

Parkinson's disease (PD) is one of the most common neurodegenerative diseases. The main pathological features of PD are the degeneration and death of dopamine neurons in the substantia nigra-striatal pathway and the accumulation of Lewy bodies in neurons. In addition to the well-known hallmark symptoms such as resting tremor and muscle rigidity, Parkinson's patients also experience non-motor symptoms such as visual disturbances, hyposmia, and sleep disturbances. At the same time, visual disturbances appear earlier than motor symptoms. The visual dysfunction in early-stage of Parkinson's disease indicates the occurrence and development of the disease. The visual dysfunction in Parkinson's disease is due to the damage of retinal dopamine neurons. This study found that magnesium sulfate supplementation can effectively delay the death of retinal dopamine neurons in 6-OHDA induced rat model of PD and improve the motor symptoms of rats with anxiety-like behavior. Therefore, magnesium sulfate may provide a new option for the early diagnosis and treatment of Parkinson's disease.

Scientific assessment

01

Research question

Assess the question within the original study’s scope.

02

Methods & sample

Check the source article for study design and sample details.

03

Key findings

An editorially approved findings summary is not yet published for this record.

04

Limitations

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.